We’re excited to welcome OBN’s BioTuesday to Alderley Park for an exciting and insightful evening focused on oncology development. As the UK's largest single site life science campus and an accelerator for the translation of emerging cancer research in the UK, this event will shine a spotlight on some of the most innovative R&D companies working within oncology in the North West region of the UK.
Presenters on the night include:
Kath Mackay, Director of Life Sciences, Bruntwood SciTech, who is instrumental in developing Bruntwood SciTech's life sciences vision and strategy, supporting its UK expansion, championing innovation and investment in high value sector R&D.
Caroline Phillips, Head of Oncology, RedX Pharma, has led the development of Redx's oncology pipeline, including progressing Redx's lead oncology asset, RXC004, a potential best-in-class, orally bioavailable porcupine inhibitor into two Phase 1 studies and signing a research collaboration with Jazz Pharmaceuticals for two targeted cancer therapies.
Oliver Schon, VP Product Development & CMC at BiVictriX Therapeutics, an emerging drug discovery and development company generating a pioneering new class of next-generation anti-cancer therapeutics which exhibit superior selectivity towards the cancer.
Andy Yates, Senior VP and Chief Scientific Officer at Artelo Bio, a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics.
Joely Irlam-Jones, Research Associate at University of Manchester, and CEO of ManTRa Diagnostics, a diagnostics development company originating from the Translational Radiobiology group, led by Professor Catharine West, and based within the Manchester Cancer Research Centre (MCRC) part of the University of Manchester.
Glen Clack, Chief Medical Officer at Evgen Pharma, who are focused on the clinical development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases
Sygnature Discovery, who have successfully delivered more than 16 pre-clinical oncology projects, utilising their integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer
More names to be announced soon...
Event Format:
18.00 Delegate registration, tea & coffee served
18.30 Welcome & Introductory keynote by Bruntwood SciTech
18.45 Keynote presentations
19.25 Company showcases
20.15 Audience Q&A
20.30 Drinks & networking
21.30 Event close